<DOC>
	<DOCNO>NCT01497223</DOCNO>
	<brief_summary>The primary objective study evaluate rate therapeutic cure combination treatment MGCD290 fluconazole compare fluconazole alone Test Cure Visit patient moderate severe vulvovaginal candidiasis .</brief_summary>
	<brief_title>MGCD290 Fluconazole Versus Fluconazole Alone Treatment Moderate Severe Vulvovaginal Candidiasis</brief_title>
	<detailed_description>MGCD290 novel antifungal agent target Hos2 enzyme fungi . MGCD290 show potentiate broaden spectrum activity azole antifungal agent vitro , especially fluconazole . MGCD290 take together fluconazole observe safe healthy volunteer study . The current study evaluate efficacy safety combination treatment subject moderate severe vulvovaginal candidiasis .</detailed_description>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidiasis , Vulvovaginal</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<criteria>Vulvovaginal candidiasis infection diagnose , symptom evaluate use numerical rating system base severity ( absent=0 ; mild=1 ; moderate=2 ; severe=3 ) minimum VVC Composite Signs/Symptoms score 7 . Subject normal vaginal pH ( â‰¤4.5 ) upon evaluation . Subject completes inform consent process . Subject agrees take study medication schedule . Subject difficulty swallow medication . Subject complies clinical trial instruction . Commits followup visit . Subject free disease physical condition might impair evaluation safety and/or vulvovaginal candidiasis . Subject childbearing potential negative urine pregnancy test screening . Subject childbearing potential agrees use effective , nonprohibited form birth control duration clinical trial onset menses follow administration study medication , whichever longer . She must stable regimen oral contraceptive , contraceptive implant depot injection , contraceptive patch , IUD , condom spermicidal agent , diaphragm spermicidal agent , sexual abstinence least past 60 day . Subject agree abstain sexual intercourse time randomization first seven day immediately follow treatment . Direct microscopic examination KOH must positive screen show yeast form ( hyphae/pseudohyphae ) budding yeast . Aged 18 , postmenarcheal , surgically naturally postmenopausal . Sensitivity ingredient study medication . Subject currently participate , within 30 day prior clinical trial participate , investigational clinical trial . Subject experience 4 episode VVC past 12 month . Subjects cause vulvovaginitis . Subjects active HPV infection . Subjects urogenital infection would potentially alter response disease . Subjects confirmed Neisseria gonorrhea Chlamydia trachomatis . Subjects abnormal PAP test result except ASCUS confirm absence HighRisk HPV infection . Subjects treatment surgery study period cervical intraepithelial neoplasia cervical carcinoma . Subjects plan major surgery time study . Pregnant nursing subject . Subjects menstruate enrollment . History hypersensitivity azoles . Evidence/history ventricular dysfunction congestive heart failure , unstable coronary artery disease , significant cardiac arrhythmia proarrhythmic condition associate prolongation QT interval . History clinically significant ECG abnormality , include QTc prolongation . Current treatment : erythromycin , astemizole , pimozide , quinidine , cisapride ) History cancer currently treat cancer . Subject immunocompromised chronic mucocutaneous candidiasis . Use systemic immunosuppressant cyclosporine , TNF inhibitor tacrolimus . History liver toxicity drug . History hepatic renal impairment . Subjects diabetes mellitus poor glycemic control ( HgbA1C &gt; 7 % ) . Subjects concurrent significant uncontrolled illness . Use oral antifungal within 14 day immediately prior enrollment . Use systemic corticosteroid within 30 day immediately prior enrollment ( inhaled corticosteroid permit ) . Use topical vaginal product within 1 week prior enrollment . Subject substance abuser abuse may result lack study compliance . Vaginal pessary ring use contraception hormone replacement therapy . Subject use antibiotic within 24 hour immediately prior enrollment .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Phase II</keyword>
	<keyword>Double-Blind</keyword>
	<keyword>Placebo-Controlled</keyword>
	<keyword>Vulvovaginal Candidiasis</keyword>
	<keyword>Moderate Severe</keyword>
	<keyword>Acute</keyword>
	<keyword>Treatment Moderate Severe Vulvovaginal Candidiasis</keyword>
</DOC>